Cost-effectiveness of paliperidone palmitate versus olanzapine, quetiapine and ziprazidone for the treatment of patients with schizophrenia under the brazilian private health care system perspective
Abstract
Authors
A.M. Nishikawa O.A.C. Clark L. Pititto